Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics

Taysha Gene Therapies Inc. (TSHA): $2.88

0.18 (-5.88%)

POWR Rating

Component Grades








Add TSHA to Watchlist
Sign Up

Industry: Biotech




#316 of 362

in industry

TSHA Price/Volume Stats

Current price $2.88 52-week high $3.89
Prev. close $3.06 52-week low $0.50
Day low $2.85 Volume 281,078
Day high $3.07 Avg. volume 2,000,300
50-day MA $1.90 Dividend yield N/A
200-day MA $1.32 Market Cap 185.66M

TSHA Stock Price Chart Interactive Chart >


  • Growth is the dimension where TSHA ranks best; there it ranks ahead of 91.16% of US stocks.
  • TSHA's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • TSHA ranks lowest in Quality; there it ranks in the 5th percentile.

TSHA Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at -10.53 for TAYSHA GENE THERAPIES INC; that's greater than it is for just 2.22% of US stocks.
  • As for revenue growth, note that TSHA's revenue has grown 283.81% over the past 12 months; that beats the revenue growth of 97.66% of US companies in our set.
  • In terms of volatility of its share price, TSHA is more volatile than 95.68% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to TAYSHA GENE THERAPIES INC, a group of peers worth examining would be PTCT, STX, ABSI, PZG, and MIMO.
  • TSHA's SEC filings can be seen here. And to visit TAYSHA GENE THERAPIES INC's official web site, go to www.tayshagtx.com.

TSHA Valuation Summary

  • In comparison to the median Healthcare stock, TSHA's price/earnings ratio is 105.87% lower, now standing at -1.6.
  • Over the past 36 months, TSHA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for TSHA.

Stock Date P/S P/B P/E EV/EBIT
TSHA 2023-09-18 20.8 -5.4 -1.6 -1.8
TSHA 2023-09-15 22.1 -5.7 -1.7 -1.9
TSHA 2023-09-14 22.7 -5.9 -1.8 -1.9
TSHA 2023-09-13 20.5 -5.3 -1.6 -1.7
TSHA 2023-09-12 20.3 -5.2 -1.6 -1.7
TSHA 2023-09-11 23.5 -6.1 -1.8 -2.0

TSHA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TSHA has a Quality Grade of D, ranking ahead of 19.38% of graded US stocks.
  • TSHA's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TSHA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -535.259
2020-12-31 0 NA -329.577

TSHA Price Target

For more insight on analysts targets of TSHA, see our TSHA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.27 Average Broker Recommendation 1.29 (Strong Buy)

Taysha Gene Therapies Inc. (TSHA) Company Bio

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

TSHA Latest News Stream

Event/Time News Detail
Loading, please wait...

TSHA Latest Social Stream

Loading social stream, please wait...

View Full TSHA Social Stream

Latest TSHA News From Around the Web

Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges with study design feasibility for potential Biologics License Application (BLA) submission Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development Strategic program prioritization will reduce operating expenses and is anticipated to extend cash runway into the fourth quarter of 2025 to support the continued

Yahoo | September 19, 2023

Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Yahoo | September 5, 2023

3 Small-Cap Stocks to Sell in September Before They Crash & Burn

A lot of speculative companies enjoyed strong rallies in the summer.

Ian Bezek on InvestorPlace | September 4, 2023

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition TSHA-102 has also received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission DALLAS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA)

Yahoo | August 24, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday!

William White on InvestorPlace | August 15, 2023

Read More 'TSHA' Stories Here

TSHA Price Returns

1-mo 44.72%
3-mo 336.36%
6-mo 323.53%
1-year 26.87%
3-year N/A
5-year N/A
YTD 27.43%
2022 -80.60%
2021 -56.10%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!